Context Therapeutics is focused on developing therapies for women's oncology, in particular breast, ovarian, and endometrial cancer. Lehr explains how the company is hoping to develop a leading pipeline of small-molecule and immuno-oncology assets to address these cancers, which is an area where the company believes there's a strong unmet clinical need.
Context Therapeutics had a large presence at AACR 2022 with five posters, more than twice the number of posters it has presented in previous years. Three of the posters addressed the company's phase 2 asset, onapristone extended release (ONA-XR), an oral progesterone antagonist, and two posters addressed its preclinical program for Claudin-6.
ONA-XR is a potent, specific progesterone receptor (PR) antagonist that has demonstrated strong efficacy across multiple PR+ solid tumor models and potential as a highly promising combination agent with standard of care therapies. Preliminary data from ONA-XR's ongoing phase 2 trials in breast, ovarian, and endometrial cancer will be reported later this year.
Also at AACR, the company made its first presentation of preclinical data for its anti-CD3 x anti-Claudin 6 (CLDN6) antigen bispecific monoclonal antibody program, highlighting the program's selectivity and potency. Context Therapeutics remains on track to complete candidate selection and initiate studies enabling an investigational new drug (IND) application by year-end.
Click on the video below to view the interview.